AR 209

Drug Profile

AR 209

Alternative Names: Anti erbB-2; OLX 209; Pseudomonas fusion toxin; ReT 9

Latest Information Update: 23 May 2001

Price : $50

At a glance

  • Originator Antigenics
  • Class Antineoplastics
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Cancer

Most Recent Events

  • 23 May 2001 AR 209 is available for licensing (http://www.aronex.com)
  • 11 Jan 2000 Discontinued-Preclinical for Breast cancer in USA (Unknown route)
  • 11 Jan 2000 Discontinued-Preclinical for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top